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ABSTRACT 
Objective: The objective of the current study was to develop and validate a simple, robust, precise and accurate RP-HPLC (reverse phase-high 
performance liquid chromatography) method for the quantitative determination of potential degradation products of Difluprednate (DIFL) in the 
ophthalmic emulsion. 
Methods: Chromatographic separation was achieved on the YMC pack ODS-AQ (150× 4.6) mm, 3μm column with a mobile phase containing a 
gradient mixture of mobile phase A (0.02M Ammonium formate buffer pH 4.5 adjusted with formic acid) and Acetonitrile as mobile phase B, at flow 
rate of 1.5 ml/min and with UV detection at 240 nm. 
Results: The peak retention time of DIFL was found at about 17.2 min, the RRT of degradation product-1 (DP-1), degradation product-2 (DP-2), and 
degradation product-3 (DP-3), were found to be about 0.49, 0.65 and 0.79 respectively (calculated with respect to Difluprednate). Stress testing was 
performed in accordance with an ICH (international council for harmonisation) guideline Q1A (R2) [1]. The method was validated as per ICH guideline 
Q2 (R1)[2]. The calibration curve was found to be linear in the concentration range of 0.1 to 0.75 µg/ml for Difluprednate, DP-1, DP-2 and DP-3. The LOD 
(Limit of detection) was found to be 0.1µg/ml and LOQ (Limit of quantification) of 0.15µg/ml for Difluprednate, DP-1, DP-2 and DP-3 respectively. The 
recovery from LOQ to 150% was within 90-110%. The forced degradation data confirms the stability indicating the nature of the method. 
Conclusion: A simple, robust, precise and accurate RP-HPLC method for the quantitative determination of potential degradation products of 
Difluprednate in the ophthalmic emulsion was developed and validated.  
Keywords: Difluprednate, Stability indicating, RP-HPLC, Degradation products, Forced degradation 






14,15,16-octahydrocyclopenta[a] phenanthren-17-yl] butanoate (fig. 
1) is a glucocorticoid receptor agonist and a diflurinated derivative of 
prednisolone having anti-inflammatory activity. DIFL ophthalmic 
emulsion is a topical formulation of DIFL that is an ophthalmic 
corticosteroid emulsion for topical instillation [4-10]. 
 
 
Fig. 1: Chemical structure of DIFL 
 
Literature survey revealed that RP-HPLC method has been reported 
for the estimation of DIFL from biological matrices, for assay in bulk 
drug as well as in eye drops [5]. The UV-Visible spectrometric 
method was also reported for estimation of DIFL [10]. DIFL and its 
formulations are not official in any pharmacopeia. 
To the best of our knowledge, no stability indicating reverse-phase high-
performance liquid chromatography [RP-HPLC] method has been 
reported for the determination of DIFL and its related impurities in the 
emulsion based eye drops. Very less work has been done on the 
quantification of related substances of DIFL in the ophthalmic emulsion; 
hence a simple robust and sensitive stability indicating RP-HPLC method 
was developed and validated for determination of DIFL and its related 
impurities in the ophthalmic emulsion as per the ICH guidelines [1-3]. 
Three potential degradation products were observed in the 
marketed products and in the degradation studies, the identified 
degradation products were enriched, isolated and purified. These 
purified degradation products were degradation product-1(DP-1), 
degradation product-2 (DP-2) and degradation product-3 (DP-3) 
which were then used to validate the method. The specification limit 
for the three degradation products and unknown impurities is 
considered as 1.0% based on the maximum daily dose as per ICH 
guideline [11]. The main aim of this research work was to develop a 
stability indicating the RP-HPLC method for determination of 
degradation products of DIFL in the ophthalmic emulsion. 
Stability indicating RP-HPLC method is defined as a validated 
method having the ability to specifically quantitate the analyte in the 
presence of excipients, degradation products, and process 
impurities. Due to the impact of stress (hydrolysis, oxidation, 
temperature and photolytic) during shelf life and instability studies, 
various degradation products shall be formed, specific quantification 
of these degradation products provides additional assurance of the 
stability indicating nature of the method [12-14]. 
MATERIALS AND METHODS 
Chemicals and reagents 
DIFL (active pharmaceutical ingredient) and DIFL ophthalmic 
emulsion were procured as a gratis sample from Sun Pharma, 
Baroda. Market samples of Flupred© were also received from Sun 
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pharma; other market samples were procured from a local 
pharmacy. Ammonium formate, formic acid and sodium hydroxide 
(AR-grade) were purchased from Merck. HPLC grade acetonitrile 
was purchased from Merck, AR-grade hydrochloric acid and 30% 
hydrogen peroxide was purchased from Rankem. DP-1, DP-2, and 
DP-3 were enriched, isolated and purified in-house. 
Instruments 
Chromatography was performed on Waters HPLC 2695 equipped 
with quaternary pumps with PDA (Photodiode array) detector. The 
chromatographic separation was performed using YMC Pack ODS-
AQ® C18 reverse phase column (150 × 3) mm, 3 µm, 110Ǻ, YMC 
Japan. Data acquisition and integrations were performed using 
empower 3 software. 
Methods 
Chromatographic conditions 
Chromatographic separation was performed in gradient mode with a 
flow rate of 1.5 ml/min consisting of mobile phase-A (0.02 M 
ammonium formate, pH 4.5) and an organic phase (Acetonitrile) as 
mobile phase-B with the column temperature set to 40 °C. The 
injection volume was 20 µl, and UV detection of DIFL and its 
degradation products was accomplished at 240 nm. The column was 
YMC pack ODS-AQ (150 × 4.6) mm, 3μm. The gradients used was 0 min 
(A-75% and B-25%), 10 min (A-55% and B-45%), 15 min (A-55% and 
B-45%), 20 min (A-20% and B-80%), 28 min (A-20% and B-80%), 30 
min (A-75% and B-25%) and 36 min (A-75% and B-25%).  
Preparation of solutions 
Preparation of buffer solution 
Dissolved 1.29 gm of Ammonium formate in 1000 ml of milli-Q 
water, sonicated for 5 min to dissolve. Adjusted the pH of the 
solution to 4.5 with diluted Formic Acid (20%v/v) and filtered 
through 0.45 µmNylon membrane filter paper. 
Preparation of standard solutions 
5 mg of DIFL was dissolved in 20 ml of acetonitrile to prepare a 
standard stock solution of 250 ppm; 2 ml of the standard stock 
solution was further diluted to 100 ml with acetonitrile (5 ppm 
system suitability solution). 
Preparation of sample solutions 
1 ml of DIFL ophthalmic emulsion 0.05% w/v was diluted up to 10 
ml with acetonitrile; sonicated the solution for 5 min and 
centrifuged at 5000 rpm for 10 min and the clear supernatant 
solution was injected in the chromatograph. 
Preparation of placebo solutions 
1 ml of placebo was diluted to 10 ml with acetonitrile; sonicated for 
5 min and centrifuged at 5000 rpm for 10 min and the clear 
supernatant solution was injected into the chromatographic system, 
and the chromatogram was recorded. 
Preparation of DP-1 stock solutions 
2.5 mg of purified DP-1 was dissolved in 10 ml of acetonitrile and 
further diluted to 50 ml with acetonitrile. 
Preparation of DP-2 stock solutions 
2.5 mg of purified DP-2 was dissolved in 10 ml of acetonitrile and 
further diluted to 50 ml with acetonitrile. 
Preparation of DP-3 stock solutions 
2.5 mg of purified DP-3 was dissolved in 10 ml of acetonitrile and 
further diluted to 50 ml with acetonitrile. 
Validation 
The optimized analytical method was validated for system 
suitability, linearity and range, precision, limit of detection, limit of 
quantitation, accuracy from LOQ to 150 % of the specification limit 
(1% for all impurities) and robustness in accordance with ICH 
guidelines for analytical procedures Q2 (R1). 
System suitability 
System suitability parameters were studied to verify the system 
performance and suitability of the method before every experiment. Six 
replicate injection of DIFL standard solution [5µg/ml] were analyzed 
using the developed method. Factors such as theoretical plate count, 
tailing factor, percent relative standard deviation [% RSD] of peak area 
and retention time were taken into consideration for testing system 
suitability. 
Linearity and range 
The linearity was evaluated at eight concentration levels in the 
range between 0.05 to 0.75 µg/ml for DIFL and three degradation 
products. A calibration curve was plotted by plotting concentration 
against corresponding peak area, and linearity was determined 
using least square regression analysis. The analytical range was 
established by the highest and lowest concentrations of analyte 
where acceptable linearity obtained. 
Accuracy and method precision 
The method precision and accuracy were carried out by preparing 
and analyzing the sample as per the method and spiking the sample 
with three impurities at 4 different level (LOQ, 50%, 100% and 
150% of specification level) in three replicates preparation at each 
level. The concentration for each impurity at LOQ, 50%, 100% and 
150% was 0.15µg/ml, 0.25µg/ml, 0.5µg/ml and 0.75µg/ml 
respectively. The percentage recovery and percentage relative 
standard deviation were taken into consideration for testing 
accuracy and precision at each level. 
Intermediate precision (Ruggedness) 
The ruggedness of the method was carried out by spiking the sample 
preparation with the three impurities at 100% level in six replicates. 
The samples were analyzed by the different analyst using the 
different column on a different system. The % RSD of the 9 
determination; three from method precision at 100% level and six 
from ruggedness has been reported.  
LOD and LOQ 
LOD and LOQ of the developed method were calculated from the 
standard deviation of the y-intercepts and slope of the calibration 









Where α is the standard deviation of the y-intercepts and S is the 
slope of the calibration curve. 
Relative response factor (RRF) 
Relative response factor of the three impurities was calculated using 






Where Si is slope of impurity standard and Ss is slope of drug 
standard. 
Forced degradation study 
Acidic degradation 
Accurately pipetted and transferred 1 ml sample solution into a 10 
ml volumetric flask, added 1 ml acetonitrile mixed and added 0.5 ml 
of 0.2M Hydrochloric acid solution and refluxed at 60 °C for 10hr, 
cooled the resulting solution at room temperature and neutralized 
the sample using 0.5 ml of 0.2M sodium hydroxide solution and 
diluted up to 10 ml with acetonitrile (50 µg/ml of DIFL). Centrifuged 
at 5000 rpm for 10 minute and the supernatant solution was 
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injected into the chromatographic system and the chromatogram 
was recorded. 
Alkaline degradation 
Accurately pipetted and transferred 1 ml sample solution into a 10 
ml volumetric flask, added 1 ml acetonitrile mixed and added 0.5 ml 
of 0.025M sodium hydroxide solution and refluxed it at 40 °C for 
6hr, cooled the resulting solution at room temperature and 
neutralized the sample using 0.5 ml of 0.025M hydrochloric acid 
solution and diluted up to 10 ml with acetonitrile (50 µg/ml of 
DIFL). Centrifuged at 5000 rpm for 10 min and the supernatant 
solution was injected into the chromatographic system, and the 
chromatogram was recorded. 
Thermal degradation  
Accurately pipetted and transferred 1 ml sample solution into a 10 
ml volumetric flask, added 1 ml acetonitrile; mixed and kept in a 
preheated oven at 80 °C for 72 hr, cooled the resulting solution at 
room temperature and diluted it up to 10 ml with acetonitrile (50 
µg/ml of DIFL). Centrifuged at 5000 rpm for 10 minute and the 
supernatant solution was injected into the chromatographic system, 
and the chromatogram was recorded. 
Oxidative degradation 
Accurately pipetted and transferred 1 ml sample solution into a 10 
ml volumetric flask, added 1 ml acetonitrile mixed and added 1 ml of 
6% hydrogen peroxide solution and refluxed it at 60 °C for 3hr, 
cooled the resulting solution at room temperature and diluted up to 
10 ml with acetonitrile (50 µg/ml of DIFL). Centrifuged at 5000 rpm 
for 10 minute and the supernatant solution was injected into the 
chromatographic system and the chromatogram was recorded. 
Photolytic degradation 
5 ml of the sample was exposed to UV light at 254 and 360 nm for 7 
d. accurately pipetted and transferred 1 ml of the exposed sample 
into a 10 ml volumetric flask, diluted up to 10 ml with acetonitrile 
(50 µg/ml of DIFL). Centrifuged at 5000 rpm for 10 min and the 
supernatant was injected into the chromatographic system and the 
chromatograms were recorded. 
RESULTS 
Method development and optimization 
The purpose of this method was to separate the potential known and 
unknown degradation products of DIFL in shorter run time. C18 
column from various manufacturers was tried, and good peak 
separation was observed in YMC pack ODS-AQ which is polar 
imbedded reverse phase column. Various buffer including 
phosphate and formate were tried in the pH range of 3.0 to 7.0. The 
gradient has been optimized after selection of suitable buffer, pH 
and column. Based on the optimization trial final method was 
developed and validated as per ICH guideline [2]. 
The optimized chromatographic condition was shown in table 1 and 
the typical HPLC chromatogram of standard and sample spiked with 
degradation product were shown in (fig. 2 and 3) and its combined 
PDA spectrum was shown in fig. 5. 
 
Table 1: Optimised chromatographic condition for the estimation of DIFL and potential degradation products 
Parameter Condition 
Mobile phase 0.02 M ammonium formate buffer pH 4.5: acetonitrile [80:20 v/v].  
Gradient Program The gradients used are 0 min (A-75% and B-25%), 10 min (A-55% and B-45%), 15 min (A-55% and B-45%), 20 min (A-
20% and B-80%), 28 min (A-20% and B-80%), 30 min (A-75% and B-25%) and 37 min (A-75% and B-25%). 
Diluent Acetonitrile 
Column YMC pack ODS AQ (150 mm × 4.6 mm) 3 μm 
Column temperature 40 °C 
Detection wavelength 240 nm 
Injection volume 20 µl 
Flow rate 1.5 ml/min 
Runtime 36 min 
 
 
Fig. 2: HPLC chromatogram of standard 
 
Method validation 
The developed method was validated as per ICH guideline [1-3]. 
System suitability 
The developed method has produced a theoretical plate above 5000 
for DIFL and three impurities with tailing factor less than 2. 
Similarly, the %RSD of peak area and retention time for DIFL peak 
was less than 5, which ensure the suitability of the developed 
method. The results of the system suitability study were 
summarised in table 2. 
Acceptance criteria 
The relative standard deviation of six replicate injections for peak 
area should not be more than 5.0%. The tailing factor should not be 
more than 2. The theoretical plates should not be less than 5000. 
Linearity and range 
Eight point calibration curve was obtained in concentration ranges 
from 0.10-0.75 µg/ml for DIFL and its three impurities. The response 
of the drug was found to be linear in the selected concentration range 
and the correlation coefficient for DIFL, DP-1, DP-2 and DP-3 were 
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found to be 0.99686, 0.99837, 99818 and 0.99802 respectively. The results of linearity were summarised in table 3. 
 
 
Fig. 3: HPLC chromatogram of sample spiked with impurities (DP-1, DP-2 and DP-3) 
 
 
Fig. 4: PDA spectrum of DIFL, DP-1, DP-2 and DP-3 
 
Precision 
The developed method had shown % RSD less than 5 for both 
method precision (precision and recovery study) and 
intermediate precision study, which ensures precision of the 
developed method. The results of the precision study were 
summarised in table 4 and 7. 
Limit of detection and limit of quantification 
LOD and LOQ were estimated from the standard deviation of the 
Y-intercepts and slope of the calibration curve of DIFL and its 
impurities. This showed that the developed method can detect 
and quantify very low concentrations of DIFL in the presence of 
its degrading products; therefore obtained data proves the 
sensitivity of the developed method for quantification of 
impurities. 
Accuracy and method precision 
The percentage recovery of the sample spiked with the known 
impurities was within 100±10%, which ensures the accuracy of the 
developed method. The results of recovery studies were summarised in 
table 5-8. 
Robustness 
As per ICH guideline, the prepared solution was analyzed as per the 
method with a small but deliberate change in chromatographic 
conditions as listed below table 9. Change in flow rate, temperature 
and pH were studied. 
 
Table 2: System suitability of the developed RP-HPLC method 
Parameters Name of drug Acceptance criteria  
DIFL DP-1 DP-2 DP-3  
Retention time 17.24 8.48 11.27 13.70 --- 
Theoretical plates [N] 109364 16524 43369 44606 >5000 
Tailing factor 0.93 0.84 0.96 0.94 <2 
Resolution NA 11.59 10.13 12.91 >2 
% RSD of Peak area* 0.41 NA NA NA <5 
% RSD of Retention time* 0.26 NA NA NA <2 
*N (Number of measurements) =6, NA: Not applicable 
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Table 3: Linearity, range and RRF of the developed RP-HPLC method 
% of specification level Conc. in µg/ml Calculated area* 
DIFL DP-1 DP-2 DP-3 
10 0.05 ND NA NA NA 
20 0.1 4.4 2 3.61 1.86 
30 0.15 4.5 3.8 4.43 3.99 
50 0.25 7.86 6.31 7.45 6.24 
80 0.4 12.81 12.04 13.03 10.97 
100 0.5 15.66 14.52 16.62 13.72 
120 0.6 17.33 18.74 20.32 17.24 
150 0.75 23.35 23.99 25.77 21.63 
Correlation Coefficient (r) 0.99686 0.99837 0.99818 0.99802 
Y intercept 1.10345 -1.14013 -0.1899 -0.60816 
%Y-Intercept 27.4132 31.6629 28.5376 27.3023 
Slope 0.56207 0.46273 0.5065 0.4774 
RRF 1 1.13 1.18 1.10 
*Calculated Area= Area count/1000, Conc: concentration, RRF: relative response factor, NA: Not applicable, ND: Not detected. 
 
Table 4: Intermediate precision (Ruggedness) of the developed RP-HPLC method 
Sample ID Component 
DP-1 DP-2 DP-3 
MP Set-1 98.8 104.0 94.1 
MP Set-2 96.4 106.1 93.8 
MP Set-3 98.8 100.2 97.3 
IP Set-1 101.3 98.2 96.6 
IP Set-2 98.7 97.4 97.0 
IP Set-3 102.9 98.1 97.2 
IP Set-4 100.3 97.5 96.9 
IP Set-5 102.0 97.0 97.1 
IP Set-6 102.3 97.7 96.4 
*Mean recovery 100.17±2.14 99.58±3.29 96.27±1.40 
% RSD 2.14 3.30 1.45 
 MP=Method precision, IP= Intermediate precision,* mean±SD (Standard deviation), N=9. 
 
Table 5: Accuracy at LOQ of the developed RP-HPLC method 
Component  Recovery at LOQ level  
% Recovery % Avg. recovery* % RSD 
Set-1 Set-2 Set-3 
DP-1 95.0 95.4 90.4 93.6±2.81 3.0 
DP-2 88.5 93.7 92.1 91.4±2.69 2.9 
DP-3 95.8 94.7 96.7 95.7±0.97 1.0 
DIFL 104.4 101.4 99.9 101.9±2.31 2.3 
*N=3, mean±SD, Avg= Average 
 
Table 6: Accuracy at 50% 
Component  Recovery at 50% of specification level 
% Recovery % Avg. recovery* % RSD 
Set-1 Set-2 Set-3 
DP-1 103.1 104.3 98.6 102.0±3.00 2.9 
DP-2 101.3 104.3 105.3 103.6±2.08 2.0 
DP-3 102.1 104.3 96.9 101.1±3.80 3.8 
DIFL 98.1 99.9 98.1 98.7±1.04 1.1 
*N=3, mean±SD, Avg= Average 
 
Table 7: Accuracyat 100% 
Component  Recovery at 100% of specification level 
% Recovery % Avg. recovery* % RSD 
Set-1 Set-2 Set-3 
DP-1 98.8 96.4 98.8 98.0±1.39 1.4 
DP-2 104.0 106.1 100.2 103.4±2.99 2.9 
DP-3 94.1 93.8 97.3 95.1±1.94 2.0 
DIFL 101.5 101.7 101.7 101.6±0.12 0.1 
*N=3, mean±SD, Avg=Average 
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Table 8: Accuracy at 150% 
Component Recovery at 150% of specification level 
% Recovery % Avg. recovery* % RSD 
Set-1 Set-2 Set-3 
DP-1 101.2 97.5 107.2 102.0±4.90 4.8 
DP-2 98.8 102.4 99.0 100.1±2.02 2.0 
DP-3 98.2 97.9 96.0 97.4±1.19 1.2 
DIFL 101.1 101.1 101.3 101.2±0.12 0.1 
*N=3, mean±SD, Avg= Average. 
 
Table 9: Robustness of the developed RP-HPLC method 
Parameter Mean area* % RSD (area) Retention* time %RSD for RT USP plate count USP tailing 
Column temperature 45◦C(+) 132.93±0.90 0.68 16.9±0.03 0.20 40207 0.87 
Column temperature 35◦C(-) 139.21±0.77 0.55 17.77±0.05 0.26 105038 0.94 
Flow rate 1.7 ml/min(+) 121.39±1.22 1.00 16.06±0.01 0.06 38335 0.93 
Flow rate 1.3 ml/min(-) 156.66±0.81 0.52 18.25±0.01 0.06 119926 0.92 
pH 4.7 (+) 150.09±2.07 1.38 16.27±0.02 0.14 65417 0.98 
pH 4.3 (-) 151.8±5.47 3.6 16.58±0.04 0.25 65305 0.95 
N=6, RT=Retention time, *mean±SD 
 
Application of the validated method for analysis of a market sample 
The developed method was used to determine the % impurities of 
the marketed samples. The results of the assay were summarised in 
table 10 and the summary of the validation parameter was 
summarised in table 11, it was confirmed that the market sample 
has the impurities. Amongst it, the major impurities were DP-1, DP-2 
and DP-3. 
 
Table 10: Related substances of DIFL in ophthalmic emulsion 
Sample details DP1 (%) DP2 (%) DP3 (%) % Unknown  %Total impurities 
DIFL Ophthalmic emulsion 0.05%w/v 0.42 0.59 0.15 0.30 1.46 
 
Table 11: Summary of validation parameters of developed RP-HPLC method 
S. No. Validation parameter DIFL DP-1 DP-2 DP-3 
1 Linearity range (µg/ml) 0.10-0.75 0.10-0.75 0.10-0.75 0.10-0.75 
2 Precision 
Method precision(%RSD)* NA 1.41 2.89 2.04 
Intermediate precision(%RSD)* NA 1.38 0.42 0.29 
3 Accuracy (% recovery)* 101.6±0.12 98.0±1.39 103.4±2.99 95.1±1.94 
4 LOD (µg/ml) 0.1 0.1 0.1 0.1 
5 LOQ (µg/ml) 0.15 0.15 0.15 0.15 
6 Specificity Specific Specific Specific Specific 
7 Robustness Robust Robust Robust Robust 
*mean±SD, Sr. No=Serial number 
 
 
Fig. 5: Chromatogram of alkali hydrolysis sample and placebo 
 
Forced degradation studies 
Forced degradation studies were carried under conditions of 
acid/base hydrolysis, oxidation, heat and photolysis. For each study, 
samples and placebo were subjected to different stress conditions. 
The concentration of the reagents and the time of exposure was 
optimized to obtain degradation within the range of 5-20%. During 
optimization of degradation conditions, excessive degradation was 
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observed in the acid, base and peroxide degradation; the conditions 
were then optimized to get degradation between 5-20% which shall 
avoid generation of secondary degradation products. 
During the forced degradation studies the sample was found to be 
very susceptible to base-catalyzed hydrolysis. The sample was also 
prone to acid catalysed hydrolysis and oxidation, which is shown in 
fig. 5-7. Throughout the degradation study, three major peaks were 
observed, which were also observed in the market sample too, these 
degradation products are then named as DP-1, DP-2 and DP-3. 
Further work in future needs to be done for the identification of 
these impurities. The degradation products observed under these 
conditions were well resolved from the drug peak. Thus the 
developed method was considered stability indicating. The 




Fig. 6: Chromatogram of acid hydrolysis sample and placebo 
 
 
Fig. 7: Chromatogram of peroxide degradation sample and placebo 
 
Table 12: Degradation behaviour of DIFL 
Condition for degradation DP1 (%) DP2 (%) DP3 (%) %Unknown  % Total degradation 
0.2M HCl at 60 °C for 10h 0.00 6.67 1.91 1.82 10.40 
0.025M NaOH at 40 °C for 6h 0.25 1.37 2.10 9.40 13.12 
Thermal degradation for 3 d 2.23 1.18 1.54 3.73 8.68 
6% Peroxide at 60 °C for 3 h 0.00 18.87 0.23 0.530 19.64 
UV light at 254 for 7d 0.00 0.00 0.00 0.00 0.00 
*HCl: Hydrochloric acid, NaOH: Sodium hydroxide. 
 
DISCUSSION 
Based on the results of forced degradation in the present study, 
three major degradation products were identified; these 
degradation products were also observed in the marketed products. 
The validation data indicates that the present work complies as per 
the ICH guideline [2]. The method was found specific, accurate, 
precise and robust for determination of all degradation products. 
The LOD and LOQ value were 0.1 and 0.15 respectively for the three 
degradation products (DP-1, DP-2 and DP-3). Low LOD and LOQ 
value indicates the sensitivity of the method for determination of 
degradation product in the ophthalmic emulsion. The high value of 
the correlation coefficient (more than 0.99) for DIFL and its 
degradation products indicates good linearity. The recovery of the 
method for the DIFL and the three impurities was found to be within 
90-110%, showing good recovery of the impurities. The precision of 
the method shows the reproducibility and repeatability of the 
method. The % RSD value for the impurities was found to be less 
than 5%, confirming the precision of the method for the quantitative 
determination of degradation products of DIFL. The specificity of the 
method to accurately quantify the degradation products of DIFL in 
the presence of the formulation components was proved by the 
forced degradation studies. The robustness data of the analytical 
method proves that the method was robust enough to deal with 
small changes in the method parameters. The methods available in 
the literature mostly focused on the assay of DIFL in the ophthalmic 
emulsion and in rabbit aqueous humor [4-10]. The present work 
specifically focused on the identification of degradation products 
and its quantification. This method can be used for evaluation of 
impurities in the market samples. 
CONCLUSION 
The developed method was stability indicating where well-resolved 
peaks were observed for analyte and degradation product. The 
method was specific, accurate, precise, and robust and can be used 
for routine quality control as well as accessing the stability of DIFL 
in bulk and in pharmaceutical dosage forms. 
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